Endocrine Adjuvant Therapy for Localized Breast Cancer

Abstract

Investigators now report in the Journal the updated results of two critical trials of endocrine therapy in early-stage breast cancer — SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) — with overlapping groups that permitted a combined analysis.1 As in many other endocrine-therapy trials, the effects were not apparent in earlier analyses, but after 8 to 9 years of follow-up, the results are clear. In premenopausal women, the addition of ovarian suppression to tamoxifen was more effective in increasing disease-free survival than tamoxifen alone, and the addition of the aromatase inhibitor exemestane to ovarian suppression was . . .